Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Amgen Inc. (NASDAQ:AMGN) is a biotechnology powerhouse with an excellent track-record on developing and commercialising products targeting four main therapeutic areas: general medicine ...

When talking about growth in the years to come, Amgen has several levers it can pull. For starters, we can look at already approved products with growth potential. Tepezza, which became part of ...

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.

Equities research analysts at William Blair reduced their FY2024 earnings per share estimates for shares of Amgen in a ...

Amgen has several products that should drive top-line growth for many years, including Tepezza, the only medicine for thyroid eye disease approved by the FDA. The company's Tezspire, the rights of ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.